Molecular interactions between the urokinase receptor and integrins in the vasculature

Fibrinolysis and Proteolysis

Volumn 12, Issue 4, 1998, Pages 205-210

  May, A E ^a,b   Kanse, S M ^a,b   Chavakis, T ^a,b   Preissner, K T ^a,b  

^a KERCKHOFF HEART CENTER   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRIN; UROKINASE RECEPTOR;

CELL INTERACTION; ENDOTHELIUM CELL; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; HEMOSTASIS; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; REVIEW; TISSUE REPAIR; VASCULAR SMOOTH MUSCLE; WOUND HEALING;

EID: 0031735388     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(98)80014-3     Document Type: Review

References (65)

1. Andreasen P A, Kjoller L, Christensen L, Duffy M J. The urokinase-type plasminogen activator system in cancer metastasis. Int J Cancer 1997; 72: 1-22.
2. Ploug M, Ronne E, Behrendt N, Jensen A L, Blasi F, Dano K. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosylphosphatidylinositol. J Biol Chem 1991; 266: 1926-1933.
3. Metz C N, Brunner G, Choi-Muira N H, et al. Release of GPI-anchored membrane proteins by a cell-associated GPI-specific phospholipase D. EMBO J 1994; 13: 1741-1751.
4. Estreicher A, Mühlhauser J, Carpentier J-L, Orci L, Vassalli J-D. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol 1990; 111: 783-792.
5. Brunner G, Preissner K T. Pericellular enyzmatic hydrolysis: implications for the regulation of cell proliferation in the vessel wall and the bone marrow. Blood Coagul Fibrinolysis 1994; 5: 625-639.
6. Ossowski L, Clunie G, Masucci M, Blasi F. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J Cell Biol 1993; 115: 1107-1112.
7. Schmitt M, Wilhelm O, Janicke F, et al. Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis. J Obstet Gynaecol 1995; 21: 151-165.
8. Duffy M J. Urokinase-type plasminogen activator and malignancy. Fibrinolysis 1993; 7: 295-302.
9. Hynes R O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11-25.
10. 3 integrin associates with activated insulin and PDGFβ receptors and potentiates the biological activity of PDGF. EMBO J 1997; 16: 5600-5607.
11. Preissner K T, May A E, Wohn K D, Germer M, Kanse S M. Molecular crosstalk between adhesion receptors and proteolytic cascades in vascular remodeling. Thromb Haemost 1997; 78: 88-95.
12. Chapman H A. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 1997; 9: 714-724.
13. Petty H R, Todd R F. Integrins as promiscuous signal transduction devices. Immunol Today 1996; 17: 209-212.
14. Springer T A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76: 301-314.
15. Altieri D C, Morrissey J H, Edgington T S. Adhesive receptor Mac-1 coordinates the activation of factor X on stimulated cells of monocytic and myeloid differentiation: an alternative initiation of the coagulation protease cascade. Proc Natl Acad Sci USA 1988; 85: 7462-7466.
16. Pöllänen J, Hedman K, Nielsen L S, Dano K, Vaheri A. Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J Cell Biol 1988; 106: 87-95.
17. Xue W, Kindzelskii A L, Todd R F, Petty H R. Physical association of complement receptor type 3 and urokinase-type plasminogen activator receptor in neutrophil membranes. J Immunol 1994; 152: 4630.
18. 2-integrins, and scr-kinases within a single receptor complex of human monocytes. J Exp Med 1995; 181: 1381-1390.
19. Sitrin R G, Todd R F, Petty H R, et al. The urokinase receptor (CD87) facilitates CD11B/CD18-mediated adhesion of human monocytes. J Clin Invest 1996; 97: 1942-1951.
20. Simon D I, Rao N K, Xu H, et al. Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells. Blood 1996; 88: 3185-3194.
21. Cao D R, Mizukami I F, Garniwagner B A, et al. Human urokinase-type plasminogen activator primes neutrophils for superoxide anion release - possible roles of complement receptor type 3 and calcium. J Immunol 1995; 154: 1817-1829.
22. Dumler I, Petri T, Schleuning W-D. Interaction of urokinase-type plasminogenactivator (u-PA) with its cellular receptor (u-PAR) induces phosphorylation on tyrosine of a 38 kDA protein. FEBS Lett 1993; 322: 37-40.
23. Busso N, Masur S K, Lazega D, Waxman S, Ossowski L. Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. J Cell Biol 1994; 126: 259-270.
24. Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, Fazioli F. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 1996; 15: 1572-1582.
25. Koshelnick Y, Ehart M, Hufnagl P, Heinrich P C, Binder B R. Urokinase receptor is associated with the components of the JAK1/STAT1 signaling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598. J Biol Chem 1997; 272: 28563-28567.
26. Dumler I, Weis A, Mayboroda O A, et al. The JAK/STAT pathway and urokinase receptor signaling in human aortic vascular smooth muscle cells. J Biol Chem 1998; 273: 315-321.
27. Gyetko M R, Sitrin R G, Fuller J A, Todd R F, Petty H, Standiford TJ. Function of the urokinase receptor (CD87) in neutrophil chemotaxis. J Leukol Biol 1995; 58: 533-538.
28. Rao N K, Shi G-P, Chapman H A. Urokinase receptor is a multifunctional protein: influence of receptor occupancy on macrophage gene expression. J Clin Invest 1995; 96: 465-474.
29. Bianchi E, Ferrero E, Fazioli F, et al. Integrin-dependent induction of functional urokinase receptors in primary T lymphocytes. J Clin Invest 1996; 98: 1133-1141.
30. Schmits R, Kundig T M, Baker D M, et al. LFA-1-deficient mice show normal CTL responses to virus, but fail to reject immunogenic tumor. J Exp Med 1996; 183: 1415-1426.
31. Sligh J E, Ballantyne C M, Rich S S, et al. Inflammatory and immune responses are impaired in mice deficient in intercellular adhesion molecule 1. Proc Natl Acad Sci USA 1993; 90: 8529-8533.
32. 3-integrins of fibrosarcoma cells - dependence on extracellular matrix components. Cancer Res 1997; 57: 1682-1689.
33. Wei Y, Lukashev M, Simon D I, et al. Regulation of integrin function by the urokinase receptor. Science 1996; 273: 1551-1555.
34. 2 integrin/LFA-1 binding to ICAM-1 induced by cytohesin-1, a cytpolasmic regulatory molecule. Cell 1996; 86: 233-242.
35. Dumler I, Hucho F, Gulba D. Signal transduction via urokinase receptor - is a transmembrane adapter molecule really necessary. Fibrinolysis & Proteolysis 1997; 11 (Suppl 2): 165-169.
36. 5-directed cell migration. J Biol Chem 1996; 271: 29393-29399.
37. Preissner K T, Pötzsch B. Vessel wall-dependent metabolic pathways of the adhesive proteins, von-Willebrand-factor and vitronectin. Histol Histopathol 1995; 10: 239-251.
38. Wei Y, Waltz D A, Rao N, Drummond R J, Rosenberg S, Chapman H A. Identification of the urokinase receptor as an adhesion receptor for vitronection. J Biol Chem 1994; 269: 32380-32388.
39. Kanse S M, Kost C, Wilhelm O G, Andreasen P A, Preissner K T. The urokinase receptor is a major vitronectin binding protein on endothelial cells. Exp Cell Res 1996; 224: 344-353.
40. de Boer H C, Preissner K T, Bouma B N, de Groot P G. Internalization of vitronectin-thrombin-antithrombin complex by endothelial cells leads to deposition of the complex into the subendothelial matrix. J Biol Chem 1995; 270: 30733-30740.
41. 5 integrin receptor regulates receptor-mediated endocytosis of vitronectin. J Biol Chem 1993; 268: 11492-11495.
42. Dahlbäck K, Löfberg H, Alumets J, Dahlbäck B. Immunohistochemical demonstration of age-related deposition of vitronectin (S-protein of complement) and terminal complement complex on dermal elastic fibers. J Invest Dermatol 1989; 92: 727-733.
43. Senger D R. Molecular framework for angiogenesis. A complex web of interactions between extravasated plasma proteins and endothelial cell proteins induced by angiogenic cytokines. Am J Pathol 1996; 149: 1-7
44. Deng G, Curriden S A, Wang S, Rosenberg S, Loskutoff D J. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?; Cell Biol 1996; 134: 1563-1571.
45. Waltz D A, Chapman H A. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem 1994; 269: 14746-14750.
46. Preissner K T. Vitronectin as link between protease cascades and cell adhesion in haemostasis. In: van Hinsbergh V W M (ed). Vascular Control of Hemostasis. Amsterdam: Harwood Academic Publications, 1996: 169-186.
47. Colman R W, Pixley R A, Najamunnisa S, et al. Binding of high molecular weight kininogen to human endothelial cells is medited via a site within domains 2 and 3 of the urokinase receptor. J Clin Invest 1997; 100: 1481-1487.
48. Asakura S, Hurley R W, Skorstengaard K, Ohkubo I, Mosher D F. Inhibition of cell adhesion by high molecular weight kininogen. J Cell Biol 1992; 116: 465-476.
49. Li C Z, Gurewich V, Liu J N. Urokinase-type plasminogen activator-induced monocyte adhesion is modulated by kininogen, kallikrein, factor XII, and plasminogen. Exp Cell Res 1996; 226: 239-242.
50. Ciambrone G J, McKeown-Longo PJ. Vitronectin regulates the synthesis and localization of urokinase-type plasminogen activator in HT-1080 cells. J Biol Chem 1992; 267: 13617-13622.
51. Kook Y H, Adamski J, Zelent A, Ossowski L. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J 1994; 13: 3983-3991.
52. Moser T L, Enghild J J, Pizzo S V, Stack M S. Specific binding of urinary-type plasminogen activator (u-PA) to vitronectin and its role in mediating u-PA dependent adhesion of U937 cells. Biochem J 1995; 307: 867-873.
53. Higazi A A-R, Upson R H, Cohen R L, et al. Interaction of single-chain urokinase with its receptor induces the appearance and disappearance of binding epitopes within the resultant complex for other cell surface proteins. Blood 1996; 88: 542-551.
54. Chavakis T, Kanse S M, Yutzy B, Lijnen H R, Preissner K T. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes. Blood 1998; 91: 2305-2312.
55. Carriero M V, Del Vecchio S, Franco P, et al. Vitronectin binding to urokinase receptor in human breast cancer. Clin Cancer Res 1997; 3: 1299-1308.
56. Lupu F, Heim D A, Bachmann F, Hurni M, Kakkar W, Kruithof E K O. Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1995; 15: 1444-1455.
57. 3 binding to vitronectin. Nature 1996; 383: 441-443.
58. Kjoller L, Kanse SM, Kirkegaard T, et al. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 1997; 232: 420-429.
59. Jänicke F, Schmitt M, Hafter R, et al. Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 1990; 4: 69-78.
60. Reilly D, Christensen K, Duch M, Nolan N, Duffy M J, Andreasen P A. Type-1 plasminogen activator inhibitor in human breast carcinomas. Int J Cancer 1992; 50: 208-214.
61. Carmeliet P, Collen D. Molecular genetics of the fibrinolytic and coagulation systems in haemostasis, thrombogenesis, restenosis and atherosclerosis. Curr Opin Lipidol 1997; 8: 118-125.
62. Mousa S A, Cheresh D A. Recent advances in cell adhesion molecules and extracellular matrix proteins: potential clinical implications. Drug Dev Ther 1997; 2: 187-199.
63. Hammes H P, Brownlee M, Joncyk A, Sutter A, Preissner K T. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat Med 1996; 2: 529-533.
64. 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995; 96: 1815-1822.
65. Min H Y, Doyle L V, Vitt C R, et al. Urokinase receptor antagonist inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 1996; 56: 2428-2433.